To include your compound in the COVID-19 Resource Center, submit it here.

Amicus bolsters rare disease gene therapy pipeline with expanded UPenn deal

Amicus has added three more rare disease gene therapy programs to its pipeline through an expansion of its deal with the University of Pennsylvania, with the option to add at least a dozen more. The company also proposed Wednesday to raise $150

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE